Dual-antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor, such as clopidogrel, is routinely given after percutaneous coronary intervention (PCI) but is associated with an increased risk for bleeding. Post-discharge bleeding after PCI is itself associated with an increased risk for mortality [ ]. Thus, tremendous effort and progress have been made in trying to minimize the duration of DAPT after PCI, especially in those at high bleeding risk (HBR).